Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
The mortality rate in cancer patients demands novel therapy. One of the novel approaches developed in recent decades includes immunotoxins. Cancer cells frequently have specific growth factor receptors/antigens overexpressed on their surface; this is the principle of selective targeting of immunotoxins. Ligands recognizing these receptors and antigens can be conjugated to modified toxins. Continuous efforts are being made (i) to investigate molecules exclusively expressed on cancer cells, (ii) to improve the specificity and efficacy of these immunotoxins, (iii) to eliminate side effects (iv) to decrease immunogenicity and (v) to improve pharmacokinetics and ensure better drug delivery.
Potala
Sirisha
S
Stem Cell & Molecular Biology Lab, Indian Institute of Technology-Madras, Chennai, India.
Sahoo
Sanjeeb K
SK
Verma
Rama S
RS
D000818:Animals; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D004167:Diphtheria Toxin; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins